SARAH TAZA: Open Payments
NPI 1285191841 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$798 in 37 payments from 11 companies in 2025. Trend: 2023 $1,105 · 2024 $745 · 2025 $798
Food & beverage: $798
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 7 | $182 |
| AstraZeneca Pharmaceuticals LP | 7 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $122 |
| Grifols USA, LLC | 3 | $63 |
| ABBVIE INC. | 2 | $56 |
| GlaxoSmithKline, LLC. | 3 | $52 |
| GENZYME CORPORATION | 2 | $51 |
| Viatris Specialty LLC | 3 | $48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $43 |
| Actelion Pharmaceuticals US, Inc. | 2 | $29 |
Products named: DUPIXENT, GLASSIA, Prolastin-C Liquid, TRELEGY ELLIPTA, AIRSUPRA, YUPELRI, FASENRA, TEZSPIRE.
Industry payments across IN — which companies pay providers there.
